In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against Acute Myeloid Leukemia
Figure 5
In vivo activity of anti-CD33.CAR-transduced EBV-CTLs against AML10. NOD/SCID mice were subcutaneously injected with ffLUC+AML10 cells, and after 5 days mice were weekly intravenously injected with either PBS, unmanipulated or anti-CD33.CAR-transduced EBV-CTLs. (a) Tumor volume was monitored weekly after D-luciferin injection using a Living Image software and was quantified as total photon flux normalized for exposure time and surface area and expressed in units of photons (p) per second per cm2 per steradian (sr). Data shown are mean ± SD of 8 mice/group; . (b) Intensity signals were log-transformed and summarized using mean ± SD at baseline and multiple subsequent time points for each group of mice. Changes in intensity of signal from baseline at each time point were calculated.
